Portfolio company Alchemab Therapeutics secured the British Business Bank's largest-ever life sciences investment to advance its AI-enabled antibody pipeline.
Alchemab Therapeutics is pioneering the next generation of antibody therapeutics by leveraging adaptive immunity to create innovative treatments for hard-to-treat diseases, focusing on neurodegenerative conditions and oncology
Alchemab Therapeutics is pioneering the next generation of antibody therapeutics by leveraging adaptive immunity to create innovative treatments for hard-to-treat diseases, focusing on neurodegenerative conditions and oncology.